Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

CALGARY, Oct. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and nine-month periods ended September 30, 2007.

Third Quarter Highlights

- Announced positive interim results from a U.K. Phase Ia/1b

combination REOLYSIN(R) and radiation trial for patients with

advanced cancers - including partial and remote responses in patients

with a variety of advanced cancers;

- Commenced patient enrolment in a multi-centre, combination

REOLYSIN(R) and docetaxel (Taxotere(R)) systemic administration trial

in the U.K.;

- In October, received approval from the U.K. regulatory authorities to

begin a combination REOLYSIN(R) and cyclophosphamide trial for

patients with advanced cancers;

- Secured two additional U.S. patents, for a total of more than 150

issued patents worldwide; and,

- Presented preclinical work at the National Cancer Research Institute

Conference in Birmingham, U.K. demonstrating for the first time how

reovirus-infected melanoma cells stimulate dendritic cells to prime

the immune system against cancer cells.

"With positive results being reported from our clinical trial program in the U.K. and the U.S., seven trials actively enrolling, an additional combination trial approved to begin and an expanding intellectual property portfolio supporting our technology, Oncolytics is looking forward to making substantial progress through the balance of 2007 and 2008," said Dr. Brad Thompson, President and CEO of Oncolytics.

Oncolytics Biotech Inc.

BALANCE SHEETS

(unaudited)

As at,

September 30, December 31,


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... DE (PRWEB) , ... July 01, 2015 , ... A ... develop new ideas to lower the barriers to innovation in life sciences R&D. The ... up to two cash prizes of US$15,000 and a period of expert mentorship from ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to provide advanced scientific research into new classes of Nanoscale Graphene-based materials poised ... Touted as 'the wonder material of the 21st Century' by the researchers who ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... Scientific Corporation (NYSE: BSX ) today announced its ... trial. This new trial follows in the tradition ... MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted ... M.D., Professor of Medicine at the University of Rochester. ...
... LEUVEN, Belgium, October 5 , ... Specialists (ASRS),Conference in New York , ... discovery and development of innovative medicines for eye,disease, vascular disease ... microplasmin intravitreal injection for the treatment of,Diabetic Macular Edema (MIVI ...
... , SEATTLE, Oct. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... of Douglas E. Williams, Ph.D., Chief Executive Officer of ... , "We are pleased to welcome Doug to our ... he will make to Oncothyreon. His extensive experience in ...
Cached Biology Technology:Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial 2Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors 2
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, a ... authentication solutions, today announced enhanced functionality of its ... solution.  The enhancements build on the native ... DigitalPersona Altus platform and provide expanded mobile ... In today,s environment of increasing cyber-attacks ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... Scientists have recorded and identified one of the most ... ice as it melts into the sea. The noise, caused ... could provide clues to the rate of glacier melt and ... Geophysicist Erin Pettit, a researcher at the University of Alaska, ...
... international team of scientists, including researchers at Columbia University Medical ... malaria parasites require for survival at each stage of infection ... approach to combating malaria, one of the world,s deadliest diseases. ... the journal Nature . "Perhaps the most ...
... the Graduate School of Excellence "Materials Science in Mainz" ... Tonhauser. Anna Maria Hofmann received the prize for work ... honored for her thesis on functional polyethylene glycols. The ... prize money of EUR 2,000 and has been given ...
Cached Biology News:Glaciers sizzle as they disappear into warmer water 2Study finds new vulnerability in malaria parasite 2MAINZ award for Anna Maria Hofmann and Christine Tonhauser 2
... H 10 O 2 S 2 ... Form: White crystalline powder Assay: greater ... By IR Melting Point: greater than ... less than or equal to 1% ...
... of an anodized aluminum body in a ... embedded in polymerized matrix. It is designed ... Synergy Multi-Detection Readers. This multi-functional test plate ... the need for tedious wet testing. Works ...
... provides excellent performance with isocratic IC ... and column heater all standard, this ... and stability. The vacuum degas option ... work. Operate in manual or automated ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: